Geneva, Switzerland and Boston, MA – February 1, 2018– ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
Category: Press release
The press releases from ObsEva
ObsEva SA to Participate in JP Morgan Healthcare Conference January 8 – 11, 2018
Geneva, Switzerland and Boston, MA – January 5, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of…
ObsEva SA to Participate in BMO Healthcare Conference December 14th 2017
Geneva, Switzerland and Boston, MA _ December 7, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and…
ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor
OBE022 is a first-in-class, oral and selective PGF2alpha receptor antagonist for the potential treatment of preterm labor to delay or…
ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
– All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months – Geneva, Switzerland and Boston, MA – November 14,…
ObsEva SA Announces the Completion of Patient Recruitment in the EDELWEISS Phase 2b Clinical Trial of OBE2109 for the Treatment of Endometriosis
Geneva, Switzerland and Boston, MA – November 7, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for…
ObsEva SA to Hold Third Quarter 2017 Financial Results and Business Update Call on November 14, 2017 and Present at Credit Suisse and Jefferies Investor Conferences in November
Geneva, Switzerland and Boston, MA – October 31, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
ObsEva SA Announces $60.0 Million Private Placement with Existing and New Investors
Geneva, Switzerland and Boston, MA – 10 October, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
ObsEva SA Announces Presentation Related to its PGF2alpha Receptor Antagonist at ACCP 2017 Annual Meeting
Phase 1 clinical trial results in healthy subjects support cardiac safety of OBE022 Geneva, Switzerland and Boston, MA – 11 September, 2017 – ObsEva SA (NASDAQ: OBSV),…
ObsEva SA Announces the Completion of Patient Recruitment in the IMPLANT2 Phase 3 Clinical Trial in Assisted Reproductive Technology Ahead of Schedule
Geneva, Switzerland and Boston, MA – 06 September, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…